
-
Theravance Biopharma NasdaqGM:TBPH Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Location: 901 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.theravance.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
382.3M
Cash
130.9M
Avg Qtr Burn
N/A
Short % of Float
18.64%
Insider Ownership
4.54%
Institutional Own.
91.75%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TRELEGY ELLIPTA Details Asthma | Approved Quarterly sales | |
YUPELRI® (revefenacin) Details Chronic obstructive pulmonary disease | Approved Quarterly sales | |
TRELEGY ELLIPTA Details Chronic obstructive pulmonary disease (COPD) | Approved Quarterly sales | |
Ampreloxetine (TD-9855) Details Multiple System Atrophy, Neurogenic orthostatic hypotension | Phase 3 Data readout | |
Nezulcitinib (TD-0903) (Janus kinase inhibitor (JAKi)) Details COVID-19, Skin disease/disorder | Failed Discontinued | |
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Inflammatory bowel disease, Inflammatory disease, Ulcerative colitis, Crohns disease | Failed Discontinued | |
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Crohns disease | Failed Discontinued |